SpyGlass Acquires AVS Manufacturing Base While BIM-IOL Phase 3 Data Remains Absent

SpyGlass Pharma Acquires AVS for IOL Manufacturing Capacity

SpyGlass Pharma, Inc. announced the acquisition of Advanced Vision Science, Inc. (AVS), a subsidiary of Santen Pharmaceutical Co., Ltd., for approximately $13 million in cash on October 1, 2026. This strategic move secures scalable commercial intraocular lens (IOL) manufacturing capacity for SpyGlass Pharma's lead product candidate, the BIM-IOL System, currently in Phase 3 registrational trials. The acquisition also aims to accelerate the expansion of SpyGlass Pharma's lens portfolio to include premium IOL options, while AVS will continue to support its existing customers and licensees like Santen and Bausch + Lomb.

• Strategic Acquisition for Manufacturing Capacity: SpyGlass Pharma's acquisition of AVS for $13 million in cash provides the company with 100% ownership of a key ophthalmic medical device manufacturer. This secures a long-term, scalable supply of world-class intraocular lenses (IOLs) and manufacturing capability for approved IOL material, which is crucial for the commercialization of its lead product candidate, the BIM-IOL System.
• Accelerated Portfolio Expansion and Innovation: The acquisition positions SpyGlass Pharma to significantly accelerate the development and production of a broader portfolio of lenses. This includes integrating premium IOL options, such as toric and extended depth-of-focus lenses, into its drug delivery system, thereby expanding treatment options for glaucoma and ocular hypertension patients beyond the current monofocal IOL.
• Continuity of AVS Operations and Existing Partnerships: AVS will maintain its operations, continuing to serve its established customer base and licensing agreements. This includes an exclusive manufacturing and supply agreement with Santen for IOLs in Japan and licensing its proprietary glistening-free hydrophobic acrylic lens material to Bausch + Lomb for their enVista® IOL line, ensuring ongoing support for global IOL companies.

Addressing Key Unmet Needs in Open-Angle Glaucoma and OHT

Recent literature highlights several persistent gaps in the management of open-angle glaucoma (OAG) and ocular hypertension (OHT), spanning adherence challenges, ocular surface tolerability, and disease subtypes where IOP reduction alone is insufficient. Emerging therapeutic strategies and device-based interventions are increasingly targeting these gaps across distinct patient populations.

• Patients with poor adherence to topical therapy: Non-compliance with lifelong topical IOP-lowering eye drops is a well-recognized driver of faster disease progression. The travoprost intracameral implant (iDose TR) addresses this directly, offering sustained drug delivery for 36 months and eliminating the need for patient dexterity and daily instillation compliance — with 81% of patients being medication free in reviewed data.

• Patients requiring multimodal IOP control: Eyes with inadequately controlled OAG are increasingly managed through combination device strategies. Studies combining iDose TR with either trabecular micro-bypass stenting (iStent infinite) or canaloplasty demonstrated mean IOP reductions from 19.0 mmHg at baseline to 15.3 mmHg at month 3 (p < 0.0001), with topical medication-free rates of 59.4% overall and 67.7% in the phacoemulsification subgroup — supporting a shift toward an interventional glaucoma paradigm.

• Patients with ocular surface disease or preservative sensitivity: Long-term use of benzalkonium chloride (BAK)-preserved prostaglandin analogues is associated with ocular surface toxicity. Preservative-free latanoprost demonstrated significantly improved tear break-up time and corneal staining scores after 3 months compared to preserved formulations, with a trend toward reduced positive matrix metalloproteinase 9 expression in tears (62.5% vs. 75.0%, P = 0.118), making this population a key target for BAK-free formulations.

• Normal-tension glaucoma (NTG) patients with primary vascular dysregulation (PVD): A clinically distinct population exists in whom progressive optic neuropathy advances despite controlled IOP. PVD-associated NTG — characterized by optic disc haemorrhages, focal notch-type cupping, and paracentral visual field defects — represents an unmet need where pharmacological strategies targeting vascular dysregulation, including calcium channel blockers, magnesium supplementation, Ginkgo biloba extract, and endothelin receptor antagonists, have demonstrated clinical benefit in selected cohorts.

• Patients at risk of retinal ganglion cell (RGC) loss beyond IOP control: Managing IOP alone does not completely halt disease progression, underscoring the need for neuroprotective strategies. Investigational approaches include hydrogen sulfide donors targeting ferroptosis via NOX2 inhibition and GPX4 regulation, as well as monoclonal antibodies targeting glial fibrillary acidic protein (GFAP) to suppress astrogliosis and neuroinflammation through inhibition of the p38 MAPK, NF-κB, and NLRP3/Caspase-1/GSDMD pathways.

Bimatoprost's Safety Profile: A Foundation for the BIM-IOL System

Bimatoprost 0.03% has been evaluated across two primary indications — glaucoma/ocular hypertension and eyelash hypotrichosis — with a consistent safety profile emerging across both. In a pooled analysis of six randomized, double-masked clinical trials of bimatoprost 0.03% for eyelash hypotrichosis (n=680), common adverse events included conjunctival hyperemia, eyelid pruritus, blepharal pigmentation, nasopharyngitis, eyelid erythema, and punctate keratitis. Most adverse events occurred early in treatment, were mild in intensity, localized to the treatment site, and reversible with treatment cessation. Discontinuations due to adverse events were low, at 3.2% for bimatoprost and 2.4% for vehicle. No new safety signals were observed, and the safety profile was consistent across studies. Dermally applied bimatoprost appears to be associated with a lower incidence of adverse events than administration as an eyedrop, a profile likely mediated by decreased exposure of ocular tissues to bimatoprost when applied dermally.

In the glaucoma setting, large observational studies of the fixed combination of bimatoprost 0.03% and timolol (BTFC) further characterize the tolerability landscape. In a combined analysis of five European observational studies (n=5,556), 90.3% of patients reported no adverse events; the most common were conjunctival hyperemia (3.2%) and eye irritation (2.8%). BTFC was rated "good" or "very good" by 92.5% of physicians and 88.0% of patients, with 96.3% of patients equally or more compliant with BTFC than with prior treatment. A separate multicenter observational study (n=1,862) similarly reported that 92% of patients experienced no adverse events, with eye irritation and ocular and conjunctival hyperemia as the most commonly reported events in more than 1% of patients. A pharmacovigilance analysis based on the FAERS database identified additional signals of note across FP receptor agonists, including iris hyperpigmentation, ocular pemphigoid, corneal endothelial cell loss, periorbital fat atrophy, corneal irritation, eyelash growth, and ocular hyperemia, with bimatoprost showing the shortest mean time to onset at 155.65 days compared to latanoprost at 344.37 days (p<0.001).

A clinically relevant and distinct safety consideration for bimatoprost is its association with prostaglandin-associated periorbital syndrome (PAPS) and periorbital structural changes. A prospective self-controlled study (n=55) evaluating bilateral instillation of prostaglandin analogs over 3–6 months found that bimatoprost had the highest incidence of PAPS among the agents studied, followed by travoprost and tafluprost, with latanoprost having the lowest incidence after three months. Visible periorbital changes — including eyelash growth and thickening, periorbital hyperpigmentation, and upper-eyelid sulcus deepening — gradually appeared after three months of medication. A retrospective case series further highlighted periorbital fat atrophy as a small but significant risk of topical ophthalmic bimatoprost 0.03% therapy, noting that such changes can be irreversible. These structural effects, alongside the well-characterized local tolerability profile, represent important considerations in the clinical and strategic assessment of bimatoprost-based therapies.

Evolving Treatment Landscape for Open-Angle Glaucoma and OHT

The treatment landscape for open-angle glaucoma (OAG) and ocular hypertension (OHT) has shifted meaningfully toward earlier, less invasive intervention, with selective laser trabeculoplasty (SLT) gaining substantial evidence as a primary therapy. The six-year results of the LiGHT Trial demonstrated that initial SLT provided better long-term disease control than eye drops, with 69.8% of eyes in the SLT arm remaining at or below target IOP without medical or surgical treatment. Disease progression was observed in 26.8% of the drops arm versus 19.6% of the SLT arm (P = 0.006), and trabeculectomy was required in 32 eyes in the drops arm compared with 13 in the SLT arm (P < 0.001). A systematic review and meta-analysis of eight randomised controlled trials (1,229 patients) further confirmed that SLT-related therapy required significantly fewer medications than medication-only treatment (mean difference: −1.06, 95% CI −1.16 to −0.96, P < 0.0000), with no significant difference in IOP reduction between the two approaches. Building on this evidence base, the ongoing COAST Trial 1 — a multicenter randomised trial enrolling 418 participants — is now comparing standard-energy versus low-energy SLT as initial therapy for newly diagnosed OHT or mild-to-moderate primary OAG, with the hypothesis that low-energy SLT will be non-inferior at 12 months.

On the pharmacological front, latanoprostene bunod (LBN) ophthalmic solution 0.024% (Vyzulta®) has emerged as a mechanistically differentiated addition to the prostaglandin class. As a nitric oxide-donating prostaglandin F2α analogue, LBN lowers IOP through a dual mechanism: latanoprost acid enhances uveoscleral outflow, while the nitric oxide-releasing metabolite relaxes the trabecular meshwork and Schlemm's canal to improve conventional outflow. In the phase III APOLLO and LUNAR trials, LBN demonstrated efficacy comparable to, and in some analyses greater than, timolol 0.5%, with sustained IOP reduction confirmed over 12 months in the JUPITER study. The most frequently reported adverse events were conjunctival hyperemia, mild ocular irritation, and instillation-site discomfort. Broader literature review has also identified NCX 470 and sepetaprost as additional novel FP receptor-targeting agents in clinical phase trials, alongside sustained drug delivery systems — including intracameral implants, punctal plugs, ocular rings, and contact lenses — designed to address compliance limitations inherent to topical therapy.

Surgical innovation has similarly expanded the continuum of care. Minimally invasive glaucoma surgery (MIGS) now encompasses distinct mechanism-based approaches — trabecular bypass, goniotomy, trabeculotomy, canaloplasty, suprachoroidal shunting, and subconjunctival filtration — each targeting different components of aqueous humor dynamics. Canal-based and trabecular interventions are considered most appropriate for mild-to-moderate OAG where enhancement of conventional outflow can achieve clinically meaningful pressure and medication reduction, while trabeculectomy and aqueous shunt surgery remain indispensable for advanced or rapidly progressive disease requiring lower target pressures. The PreserFlo MicroShunt, registered in Europe since 2019 for patients with early-to-advanced OAG uncontrolled on maximum tolerated medication, represents a further evolution within minimally invasive bleb surgery, offering meaningful IOP reduction with a high safety profile. Across all modalities, the emerging framework emphasises individualised procedure and therapy selection guided by glaucoma stage, target pressure, outflow pathway integrity, and long-term surgical sequencing — a precision-based paradigm that reflects the breadth of evidence generated over the past several years.

SpyGlass's Strategic Acquisition: A New Vision for Glaucoma and IOLs

SpyGlass Pharma's strategic acquisition of Advanced Vision Science (AVS) marks a pivotal moment in its journey to reshape ocular care, particularly in the intersection of glaucoma and cataract management. By securing AVS's manufacturing capabilities, SpyGlass is not merely acquiring assets; it is fortifying the commercial pathway for its lead product, the BIM-IOL System. This innovative system, likely a sustained-release bimatoprost-eluting intraocular lens, holds the promise of revolutionizing glaucoma treatment. Research consistently highlights the challenges of patient adherence with daily eye drops and the significant benefits of sustained-release bimatoprost in maintaining consistent intraocular pressure reduction over extended periods. An IOL-based delivery system, implanted during routine cataract surgery, could offer an elegant, passive solution, effectively treating glaucoma while simultaneously restoring vision, thereby improving patient outcomes and quality of life.

Beyond the BIM-IOL, this acquisition strategically positions SpyGlass to expand its portfolio into premium IOL options, diversifying its market presence. However, this ambitious expansion is not without its considerations. The BIM-IOL System is still undergoing Phase 3 trials, and its long-term safety and efficacy as a drug-eluting IOL must be definitively established. Furthermore, the historical observation of rare 'steam-like clouding' with AVS's XACT lens, though infrequent, underscores the importance of rigorous quality control and potential R&D investment to ensure product integrity and maintain physician confidence. Successfully integrating AVS's operations while simultaneously driving innovation and scaling production for multiple IOL lines will require meticulous execution. Ultimately, this move signals SpyGlass's intent to be a formidable player, offering comprehensive, advanced solutions that bridge the gap between surgical intervention and chronic disease management in ophthalmology.